The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citationPostantibiotic Suppression of Bacterial Growth
Bundtzen, R. W., Gerber, A. U., Cohn, D. L., & Craig, W. A. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.28 · Cited by 311
Self-citationKilling and regrowth of bacteria in vitro: a review.
Craig, W. A., & Ebert, S. C. (1990) · PubMed · Cited by 303
Self-citationIn Vivo Postantibiotic Effect in a Thigh Infection in Neutropenic Mice
Vogelman, B., Gudmundsson, S., Turnidge, J., Leggett, J., & Craig, W. A. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.2.287 · Cited by 259 · cited 2×
“Second, prolonged PAEs are observed in vitro but not in vivo after streptococci are exposed to penicillin and cephalosporins [16, 17, 20].”
Self-citationPharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
Craig, W. A., Redington, J., & Ebert, S. C. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.suppl_c.29 · Cited by 238 · cited 3×
“-time curve (AUC) but eliminated with a half-life of 20 minutes in mice [19].”
Self-citationPersistent Effect of Antibiotics on Staphylococcus aureus after Exposure for Limited Periods of Time
McDonald, P. J., Craig, W. A., & Kunin, C. M. (1977) · Journal of Infectious Diseases · doi:10.1093/infdis/135.2.217 · Cited by 196 · cited 1×
“These persistent effects include the postantibiotic effect (PAE), the postantibiotic sub-MIC effect (PAE-SME), and the postantibiotic leukocyte enhancement (PALE) [5-7].”
Self-citationMcDonald, P. J., Wetherall, B. L., & Pruul, H. (1981) · Clinical Infectious Diseases · doi:10.1093/clinids/3.1.38 · Cited by 187 · cited 3×
“This phenomenon can also prolong the duration of the PAE, both in vitro and in vivo [7, 10].”
Paladino, J. A., Sperry, H. E., Backes, J. M., Gelber, J. A., Serrianne, D. J., Cumbo, T. J., & Schentag, J. J. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90181-v · Cited by 163 · cited 1×
“A peak/MIC ratio of 8-10 has also been shown both in vitro and in vivo to prevent the emergence of resistant mutants during therapy with fluoroquinolones [54, 55].”
Daikos, G. L., Lolans, V. T., & Jackson, G. G. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.1.117 · Cited by 163 · cited 1×
“During the period of down-regulation, decreased killing of bacteria and higher MICs are exhibited [57].”
DAGAN, R., ABRAMSON, O., LEIBOVITZ, E., LANG, R., GOSHEN, S., GREENBERG, D., YAGUPSKY, P., LEIBERMAN, A., & FLISS, D. M. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199611000-00010 · Cited by 162 · cited 2×
“There have been a reasonable number of clinical trials that have included routine repeated tympanocentesis of middle ear fluid after 2-7 days of therapy to determine whether the infecting organism was eradicated [39-42].”
Microbiologic efficacy of antibacterial drugs for acute otitis media
Klein, J. O. (1993) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199312000-00001 · Cited by 149
ter Braak, E. W. M. T., de Vries, P. J., Bouter, K. P., van der Vegt, S. G. L., Gc, D., Nortier, J. W. R., van Dijk, A. P. J., Verkooyen, R. P. A. J., & Verbrugh, H. A. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90099-y · Cited by 148
Craig, W. A. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.suppl_d.149 · Cited by 147 · cited 4×
“The PAE has also been demonstrated in vivo in a variety of animal infection models [16].”
InfluentialSelf-citationPostantibiotic effect of imipenem on Pseudomonas aeruginosa
Bustamante, C. I., Drusano, G. L., Tatem, B. A., & Standiford, H. C. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.5.678 · Cited by 146 · cited 1×
“aeruginosa [14, 15].”
THE SLOW RECOVERY OF BACTERIA FROM THE TOXIC EFFECTS OF PENICILLIN
Eagle, H., & Musselman, A. D. (1949) · Journal of Bacteriology · doi:10.1128/jb.58.4.475-490.1949 · Cited by 129 · cited 1×
“PAE can be considered the time it takes for an organism to recover from the effects of exposure to an antimicrobial; this phenomenon was first described in the 1940s with regard to the activity of penicillin against staphylococci and streptococci [11-13], but these early observations were not applied to newer drugs an…”
Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin
Odenholt-Tornqvist, I., Löwdin, E., & Cars, O. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.9.1852 · Cited by 114 · cited 2×
“These persistent effects include the postantibiotic effect (PAE), the postantibiotic sub-MIC effect (PAE-SME), and the postantibiotic leukocyte enhancement (PALE) [5-7].”
Antimicrobial resistance issues of the future
Craig, W. A. (1996) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(96)00162-9 · Cited by 114
Self-citationRoosendaal, R., Bakker‐Woudenberg, I. A. J. M., van den Berg, J. C., & MICHEL, M. F. (1985) · The Journal of Infectious Diseases · doi:10.1093/infdis/152.2.373 · Cited by 110 · cited 1×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
The post-antibiotic sub-MIC effect in vitro and in vivo
Cars, O., & Odenholt-Tornqvist, I. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.suppl_d.159 · Cited by 107
Weinstein, M. P., Stratton, C. W., Hawley, H. B., Ackley, A. M., & Reller, L. B. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90688-7 · Cited by 102 · cited 2×
“Data are from [47] and [48].”
The bactericidal action of penicillin on staphylococcus pyogenes
Bigger, J. W. (1944) · Irish Journal of Medical Science (1971 -) · doi:10.1007/bf02948462 · Cited by 101
Fantin, B., Leggett, J., Ebert, S. C., & Craig, W. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.7.1413 · Cited by 97 · cited 1×
“The 24-hour AUC/MIC ratio is the parameter that best correlates with the efficacy of the fluoroquinolones [25, 26, 51].”
Self-citationPharmacodynamic Properties of Antibiotics: Application to Drug Monitoring and Dosage Regimen Design
Ebert, S. C., & Craig, W. A. (1990) · Infection Control and Hospital Epidemiology · doi:10.1086/646178 · Cited by 91 · cited 1×
“activity over time is an important determinant of effective dosage regimens [4].”
Self-citationTäuber, M. G., Zak, O., Scheid, W. M., Hengstler, B., & van de Sande, M. A. J. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/149.4.575 · Cited by 91 · cited 1×
“Second, prolonged PAEs are observed in vitro but not in vivo after streptococci are exposed to penicillin and cephalosporins [16, 17, 20].”
In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media
Géhanno, P., Lenoir, G., & Berche, P. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.271 · Cited by 91 · cited 1×
“ologic cure or clinical cure were used as end points [42, 44, 45].”
Fantin, B., Ebert, S. C., Leggett, J., Vogelman, B., & Craig, W. A. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.6.829 · Cited by 91 · cited 1×
“First, the length of the in vitro PAE is not predictive of the duration of the in vivo PAE [10, 18].”
Self-citationThe in-vivo postantibiotic effect of imipenem and other new antimicrobials
Gudmundsson, S. R., Vogelman, B., & Craig, W. A. (1986) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/18.supplement_e.67 · Cited by 85 · cited 1×
“aeruginosa [14, 15].”
Self-citationThe Action of Penicillin onStaphylococcus:Further Observations on the Effect of a Short Exposure
Parker, R. F., & Luse, S. A. (1948) · Journal of Bacteriology · doi:10.1128/jb.56.1.75-81.1948 · Cited by 78 · cited 1×
“PAE can be considered the time it takes for an organism to recover from the effects of exposure to an antimicrobial; this phenomenon was first described in the 1940s with regard to the activity of penicillin against staphylococci and streptococci [11-13], but these early observations were not applied to newer drugs an…”
Fantin, B., & Carbon, C. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.12.2387 · Cited by 75 · cited 1×
“Experimental studies of enterococcal endocarditis have shown a greater reduction in bacterial numbers in vegetations when an aminoglycoside is administered in multiple-dosing regimens than in once-daily regimens [63, 64].”
Huy, P. T. B., & Deffrennes, D. (1988) · Acta Oto-Laryngologica · doi:10.3109/00016488809119511 · Cited by 64 · cited 1×
“Uptake of these drugs into renal tubular cells and the endolymph of the ear is more efficient with low sustained concentrations than with high intermittent levels [58, 59].”
In Vivo Sensitivity Test in Otitis Media: Efficacy of Antibiotics
Howie, V. M., Dillard, R. A., & Lawrence, B. L. (1985) · PEDIATRICS · doi:10.1542/peds.75.1.8 · Cited by 63
Hoberman, A., Paradise, J. L., Block, S. L., BURCH, D. J., Jacobs, M. R., & BALANESCU, M. I. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199610000-00034 · Cited by 61
Gilbert, D. N. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.816 · Cited by 57
Role of Antimicrobial Pharmacokinetics and Pharmacodynamics in Surgical Prophylaxis
Redington, J. J., Ebert, S. C., & Craig, W. A. (1991) · Clinical Infectious Diseases · doi:10.1093/clinids/13.supplement_10.s790 · Cited by 54 · cited 1×
“The AUC of unbound drug in skin-blister fluid is usually similar to that in serum [35].”
Self-citationComparison of cefotaxime and moxalactam pharmacokinetics and tissue levels
Wise, R. A., Baker, S., & Livingston, R. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.18.3.369 · Cited by 50 · cited 1×
“trations i these sites will lag behind those in serum, resulting in lower peak levels but higher trough concentrations [32-34].”
Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus
Shah, P., Junghanns, W., & Stille, W. (1976) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0028-1104083 · Cited by 49
Ryan, D. M., Hodges, B., Spencer, G. R., & Harding, S. M. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.22.6.995 · Cited by 44 · cited 2×
“trations i these sites will lag behind those in serum, resulting in lower peak levels but higher trough concentrations [32-34].”
In vitro postantibiotic effect following repeated exposure to imipenem, temafloxacin, and tobramycin
McGrath, B. J., Marchbanks, C. R., Gilbert, D., & Dudley, M. N. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.8.1723 · Cited by 30 · cited 1×
“Third, the results of in vitro studies that suggest that the PAE of aminoglycosides decreases and disappears over a prolonged dosing interval or with repeated doses have not been observed in in vivo studies [21, 22].”
den Hollander, J. G., Mouton, J. W., van Goor, M. P., Vleggaar, F. P., & Verbrugh, H. A. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.784 · Cited by 25 · cited 1×
“Third, the results of in vitro studies that suggest that the PAE of aminoglycosides decreases and disappears over a prolonged dosing interval or with repeated doses have not been observed in in vivo studies [21, 22].”
The pharmacokinetics of ceftriaxone in serum, skin blister and thread fluid
Kalager, T., Digranes, A., Bergan, T., & SOLBERG, C. O. (1984) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/13.5.479 · Cited by 20 · cited 2×
“trations i these sites will lag behind those in serum, resulting in lower peak levels but higher trough concentrations [32-34].”
Kinetics of antibiotics in relation to effective and convenient outpatient parenteral therapy
Craig, W. A. (1995) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(94)00048-y · Cited by 19 · cited 2×
“Data are from [47] and [48].”
Self-citation
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
“With the use of in vitro and in vivo evaluations, antibiotics are categorized on the basis of whether they possess concentration-dependent or timedependent effects on microorganisms and on the basis of 4 common PK/PD parameters that predict antibiotic efficacy: the ratio of the maximum serum concentration to the MIC,…”
MethodRybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Self-citationLebeaux, D., Ghigo, J.-M., & Beloin, C. (2014) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00013-14 · Cited by 1,318
Clinical Practice Guideline (Update): Adult Sinusitis
Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper, M., Orlandi, R. R., Palmer, J. N., Patel, Z. M., Peters, A., et al. (2015) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815572097 · Cited by 1,159
Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu027 · Cited by 1,090
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
Background
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.